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Accepted 9 December 2016; Published online xxxxAbstractObjectives: To compare the methodological and reporting quality of systematic reviews by authors from China and those from the
United States (USA).
Study Design and Setting: From systematic reviews of randomized trials published in 2014 in English, we randomly selected 100
from China and 100 from the USA. The methodological quality was assessed using the Assessing the Methodological Quality of
Systematic Reviews (AMSTAR) tool, and reporting quality assessed using the Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) tool.
Results: Compared with systematic reviews from the USA, those from China were more likely to be a meta-analysis, published in low-
impact journals, and a non-Cochrane review. The mean summary Assessing the Methodological Quality of Systematic Reviews score was
6.7 (95% confidence interval: 6.5, 7.0) for reviews from China and 6.6 (6.1, 7.1) for reviews from the USA, and the mean summary
Preferred Reporting Items for Systematic Reviews and Meta-analyses score was 21.2 (20.7, 21.6) for reviews from China and 20.6
(19.9, 21.3) for reviews from the USA. The differences in summary quality scores between China and the USA were statistically nonsig-
nificant after adjusting for multiple review factors.
Conclusion: The overall methodological and reporting quality of systematic reviews by authors from China are similar to those from
the USA, although the quality of systematic reviews from both countries could be further improved.  2017 The Author(s). Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Well-conducted systematic reviews and meta-analyses
of randomized controlled trials (RCTs) provide the most
valid research evidence on effects of health care interven-
tions [1,2]. Systematic review methods (with or without
meta-analysis) have been used in medicine and health
research since later 1980s in developed countries [3]. The
Cochrane Collaboration and other evidence-based health
programs have promoted the use of systematic reviewing
methods globally [4], including China [5].Funding: There was no specific funding for this study.
Conflict of interest: None.
* Corresponding author. Tel.:þ44 1603 591253; fax:þ44 1603 593752.
** Corresponding author. Tel.:þ86 931 8912767; fax:þ86 931 8915076.
E-mail addresses: Fujian.song@uea.ac.uk (F. Song), yangkh@
lzu.edu.cn (K. Yang).
http://dx.doi.org/10.1016/j.jclinepi.2016.12.004
0895-4356/ 2017 The Author(s). Published by Elsevier Inc. This is an open ac
licenses/by-nc-nd/4.0/).It has been anticipated that systematic reviews would
help address challenges due to rapid increase in clinical
literature [6,7]. However, the successful production of
systematic reviews during past decades has raised
concerns about whether the exponential increase in
published systematic reviews might have actually exacer-
bated information overload [7e11]. Particularly, the
increased production of systematic reviews by authors from
China has been considered at least partly responsible for the
rapid increase in systematic reviews globally [12,13]. For
example, a search in PubMed on January 8, 2016 (see
Supplementary File 1 at www.jclinepi.com for the search
strategy), found that the number of published systematic
reviews by authors from China was increased exponentially
from only 19 in 2005 to 1,073 in 2014. During the same
time period, the production of systematic reviews by
authors from the United States (USA) was only moderately
increased from 500 in 2005 to 796 in 2014.cess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 The overall methodological and reporting quality
of systematic reviews of randomized trials by au-
thors from China were similar to those from the
United States (USA). The differences and similar-
ities in specific quality items between China and
the USA were identified.
What this adds to what was known?
 This is the first study to compare the reporting and
methodological quality of systematic reviews of
randomized trials by authors from China (a devel-
oping country) and the USA (a developed country).
What is the implication and what should change
now?
 Considering the usefulness of systematic reviews
in evidence-based practice and the development
of primary research, the systematic reviewing ca-
pacity should be strengthened in China. Identified
shortcomings in methodological and reporting
quality of published systematic reviews should be
considered in further training of authors of system-
atic reviews in the relevant countries.
With the rapid increase in the number of systematic
reviews by authors from China, their reporting and method-
ological quality have been scrutinized in the previous
studies [12,14e18]. These studies usually suggested that
the reporting and methodological quality of systematic
reviews from China were poor and needed to be much
improved. However, it is unclear about the quality of sys-
tematic reviews by authors from China relative to those
from other countries. There was only one previous study
that compared meta-analyses of genetic associations by
authors from China and those from the USA [10,12].
According to our knowledge, there were no published
studies that systematically compared quality of systematic
reviews of RCTs of health care interventions by authors
from China and those by authors from other countries.
Identification of differences in methodological and
reporting quality of systematic reviews by authors from
China and developed countries may help appropriately
interpret findings from systematic reviews and set priorities
in training of systematic reviewers. Specifically, we
consider it appropriate to compare systematic reviews by
authors from China and those from the USA for the
following reasons: Authors from the USA, along with
authors from other high-income nations, have been
traditionally the main producer of systematic reviews, and
a previous study had compared genetic associationmeta-analyses by authors from China and the USA [12].
Therefore, the aim of the current study is to compare the
main characteristics, methodological, and reporting quality
of systematic reviews of health care interventions between
China and the USA. Although the reporting quality was
assessed, the focus of the current study was on the method-
ological quality regarding the validity in the process and
results of a systematic review.2. Methods
2.1. Identification and selection of systematic reviews
One reviewer (F.S.) searched PubMed on January 8,
2016, to identify relevant systematic reviews (see
Supplementary File 1 at www.jclinepi.com for the search
strategy). Citations of all identified systematic reviews
were downloaded to an EndNote database and then
exported to a Microsoft Excel spreadsheet. Each of the
originally identified records by country was assigned a
random number from 0 to 1 (generated by Excel). Then,
the records were ordered from the smallest to the largest
by assigned random numbers, and the first 100 eligible sys-
tematic reviews from each country were selected. If a
selected systematic review was not eligible, a successive
record was used to replace it until the total number of
included systematic reviews was 100 for each country.
Included systematic reviews met the following criteria:
(1) was a review article and explicitly stated as a system-
atic review or meta-analysis, with a formal (comprehensive
or not) literature search, (2) was fully published in English
in 2014, (3) included only RCTs, and (4) had a correspond-
ing author with an affiliation in mainland China or in the
USA. We did not formally calculate the number of system-
atic reviews required because of no information on what
would be clinically meaningful differences in quality of
systematic reviews between countries.
2.2. Quality assessment and data extraction
All authors involved in this study had previous experi-
ence of assessing quality of published systematic reviews.
Using a data extraction sheet (Supplementary File 1 at
www.jclinepi.com), one reviewer (I.Z., L.G., or J.H.T.)
extracted and a second reviewer (J.H.T. or F.S.) checked
data on the main characteristics from included systematic
reviews. Any disagreements were resolved by discussion.
Data extracted from systematic reviews included the
following: the journal in which a systematic review was
published, type of systematic reviews (narrative or meta-
analysis), the number of authors, countries which coauthors
came from, whether the review protocol was registered,
diseases of interest, interventions evaluated, primary
outcome measures, the number of RCTs included, the num-
ber of total participants, and conclusions of the systematic
reviews. Impact factors of journals in which systematic
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Journal Citation Reports (Thomson Reuters, 2016) in Web
of Science.
The methodological quality of a systematic review
reflects risk of bias or validity in its process and results. Pre-
vious studies found that the Assessing the Methodological
Quality of Systematic Reviews (AMSTAR) tool is reliable
and valid [19e21]. Therefore, we used AMSTAR tool to
assess the methodological quality of the included system-
atic reviews. The reporting quality of a systematic review
refers to the clarity and transparency of its reporting, and
poor reporting reduces the value and usefulness of system-
atic reviews [22]. We used the Preferred Reporting Items
for Systematic Reviews and Meta-analyses (PRISMA)
checklist to assess the reporting quality of the included
systematic reviews [23]. The methodological quality assess-
ment using the AMSTAR tool was conducted by two
independent reviewers (J.H.T. and F.S.), and the reporting
quality assessment using the PRISMA tool was conducted
by one reviewer (J.Z. or L.G.) and checked by a second
reviewer (J.H.T. or F.S.). Any disagreements between
reviewers were resolved by discussion or the involvement
of a third reviewer.
To examine the agreement between the two independent
reviewers in the assessment of methodological quality of
systematic reviews, we calculated the agreement proportion
and Cohen’s kappa value for each of the 11 AMSTAR items.2.3. Data analysis methods
The main characteristics and quality of systematic
reviews from China vs. those from the USAwere tabulated.
We compared the quality of systematic reviews between
China and the USA by individual items of the AMSTAR
and PRISMA instrument. We calculated a summary
AMSTAR score for each systematic review according to
the method used by Shea et al. [20]: For each of the 11 items
of the AMSTAR checklist, it was scored ‘‘1’’ if the answer
was ‘‘Yes,’’ and ‘‘0’’ if the answer was ‘‘No’’ or ‘‘Can’t
tell.’’ Some items may be relevant mainly to meta-
analysis, such as the use of funnel plot and related statistical
test for assessing publication bias. It was scored ‘‘1’’ if a
narrative discussion of risk of publication bias was available
in systematic reviews when the use of funnel plot was
impossible or inappropriate. The summary AMSTAR score
for a systematic review was calculated by counting the num-
ber of ‘‘Yes’’ answers, with a possible maximum score of
11. For the assessment of reporting quality of systematic
reviews, each of the 27 PRISMA items was scored ‘‘1’’
for full compliance, ‘‘0.5’’ for partial compliance, and ‘‘0’’
for noncompliance [15]. The summary PRISMA score for
a systematic review was calculated by adding up scores
assigned to each item, with a maximum score of 27.
Chi-squared test was used for differences in proportions
(or Fisher’s exact test if a contingency table contained a cell
with five or fewer events). Two sample Wilcoxon rank-sumtest or Student t-test was used for differences in continu-
ously distributed variables. The summary AMSTAR scores
and the summary PRISMA scores were ranked into three
groups: low (up to the 25th percentile), moderate (the inter-
quartile range), and high (the 75th percentile and above).
The association between the summary quality scores and
country was calculated in either bivariate or multiple vari-
able linear regression analyses after adjusting for factors
with imbalanced distribution between China and the
USA. Analyses were conducted by using data from all
included systematic reviews and using data from only
non-Cochrane systematic reviews. Statistical significance
was defined as two sided P ! 0.05. We used Stata/IC
version 14.1 for statistical analyses.3. Results
The search of PubMed on January 8th 2016 identified
1,073 records of systematic reviews published in 2014 from
China and 796 from the USA. The references and main
characteristics of the randomly selected systematic reviews
are available in Supplementary File 2 at www.jclinepi.com.
3.1. Characteristics of included systematic reviews
The main characteristics of the included systematic
reviews are summarized in Table 1. Compared with sys-
tematic reviews from the USA, those from China were
more likely to contain a quantitative meta-analysis, less
likely to be a Cochrane systematic review, and tended to
be published in journals with lower impact factors. Sys-
tematic reviews from China were more likely to have four
or more coauthors, but much less likely to include coau-
thors from other countries. The proportion of systematic
reviews with a registered review protocol was lower for
systematic reviews from China, although the difference
was no longer significant after excluding Cochrane sys-
tematic reviews.
There were statistically significant differences in disease
conditions investigated. Compared with reviews from the
USA, reviews from China were more likely to investigate
cancer or tumor diseases and less likely to study mental
or behavioral disorders. In terms of interventions evaluated,
systematic reviews from China focused less on pharmaco-
logical interventions and more on surgical interventions
and alternative medicine. Systematic reviews from China
provided somewhat more significant or positive conclusions
and less uncertain conclusions, although the overall differ-
ence was statistically nonsignificant.
3.2. Results of methodological quality
Two reviewers independently assessed the methodolog-
ical quality and proportions of agreement on the initial AM-
STAR assessment were greater than 65% for 10 of the 11
AMSTAR items (see Supplementary File 3 at www.
Table 1. The main characteristics of the included systematic reviews
Characteristics
All systematic reviews Non-Cochrane reviews
China (n [ 100) USA (n [ 100) P value China (n [ 92) USA (n [ 74) P value
Meta-analysis (%) 97.0 77.0 *** 100 74.3 ***
Cochrane systematic reviews (%) 8.0 26.0 ***
Journal impact factors: median
(IQR)
2.7 (1.5, 3.2) 3.7 (2.4, 6.0) *** 2.4 (1.4, 3.2) 3.0 (2.2, 4.0) ***
No. of authors (%) *** ***
1 to 3 authors 8.0 34.0 7.6 31.1
4 to 6 authors 60.0 43.0 62.0 41.9
7 or more authors 32.0 23.0 30.4 27.0
Authors from 2 or more
countries (%)
12.0 98.0 *** 10.9 100 ***
Review protocol registered (%) 12.0 29.0 ** 4.4 5.4 N.S.
Type of primary outcomes (%)
Objectively measured 42.0 42.0 N.S. 39.1 28.4 N.S.
Subjectively measured 12.0 11.0 12.0 12.2
Not defined or unclear 46.0 47.0 48.9 59.5
No. of RCTs included: median
(IQR)
8 (6, 13) 9 (5, 16) N.S. 8 (6, 13) 10 (6, 17) N.S.
No. of patients included: median
(IQR)
976 (514, 2124) 1552 (506, 6477) N.S. 976 (519, 2184) 2303 (585, 12129) **
Conditions investigateda (%)
Circulatory 21.0 18.0 * 20.7 17.6 *
Neoplasms 24.0 8.0 26.1 9.5
Digestive 13.0 9.0 10.9 8.1
Endocrine/nutritional/metabolic 7.0 7.0 7.6 8.1
Respiratory system 7.0 8.0 6.5 5.4
Mental/behavioural 4.0 11.0 4.4 14.9
Musculoskeletal/connective 6.0 8.0 6.5 8.1
Genitourinary 7.0 5.0 6.5 5.4
Any other 11.0 27.0 10.9 23.0
Type of interventions (%)
Pharmacological 53.0 69.0 N.S. 51.1 66.2 *
Surgical 13.0 5.0 14.1 4.1
Device 9.0 6.0 7.6 8.1
Disease management 6.0 6.0 6.5 6.8
Psycho-educational 0.0 4.0 0.0 5.4
Alternative/traditional 10.0 6.0 10.9 6.8
Any other 9.0 4.0 9.9 2.7
Review authors’ conclusionb (%)
Significant/positive 78.0 63.0 N.S. 80.4 68.9 N.S.
Non-significant 10.0 14.0 9.8 13.5
Unclear/lack of evidence 12.0 23.0 9.8 17.6
Abbreviations: ICD, International Classification of Diseases; IQR, interquartile range.
a Conditions were grouped according to ICD-10.
b Significant/positive conclusions e significant differences found or at least one intervention recommended; Non-significant conclusions e no
significant differences found or no interventions recommended; Unclear conclusions e lack of evidence or neither positive nor negative, or not able
to judge. Chi-square test was used for categorical variables and two sample Wilcoxon rank sum test for continuously distributed variables.
N.S. 5not statistically significant, * P!0.05, ** P!0.01, *** P!0.001.
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conflict of interests was mainly due to different understand-
ing of definition for this item. All disagreements were
resolved by discussion, and results of the assessment of
the methodological quality are shown in Table 2.
Differences between systematic reviews from China and
the USA were statistically significant for seven of the 11
AMSTAR items. The methodological quality of systematic
reviews from one country was not consistently lower or
higher than another country for all AMSTAR items.
Compared with systematic reviews from the USA, themethodological quality of reviews from China was rela-
tively poor in terms of a priori design, comprehensive liter-
ature search, listing both included and excluded studies,
and stating sources of support in both the review and
included primary studies. On the contrary, systematic re-
views from China showed better quality in terms of dupli-
cate study selection, duplicate data extraction, the
assessment of scientific quality, and using scientific quality
in formulating conclusions. After excluding Cochrane sys-
tematic reviews, differences in the methodological quality
remained unchanged in general (Table 2).
Table 2. The methodological quality of systematic reviews by country e results of the AMSTAR checklist assessment
AMSTAR item
All systematic reviews Non-Cochrane review
China
(n [ 100) %
USA
(n [ 100) % P value
China
(n [ 92) %
USA
(n [ 74) % P value
1. Was a priori design provided? 11.0 34.0 *** 4.4 12.2 N.S.
2. Was there duplicate study selection
and data extraction?
97.0 73.0 *** 96.7 67.6 ***
3. Was a comprehensive literature search
performed?
78.0 91.0 * 76.1 87.8 N.S.
4. Was the status of publication (i.e. grey
literature) used as an inclusion
criterion?
27.0 31.0 N.S. 21.7 18.9 N.S.
5. Was a list of studies (included and
excluded) provided?
12.0 40.0 *** 5.4 21.6 **
6. Were the characteristics of the
included studies provided?
100 99.0 N.S. 100 98.7 N.S.
7. Was the scientific quality of the
included studies assessed and
documented?
97.0 75.0 *** 97.8 66.2 ***
8. Was the scientific quality of the
included studies used appropriately in
formulating conclusions?
80.0 51.0 *** 79.4 37.8 ***
9. Were the methods used to combine the
findings of studies appropriate?
100 95.0 N.S. 100 93.2 *
10. Was the likelihood of publication bias
assessed?
63.0 51.0 N.S. 63.0 47.3 *
11. Was the conflict of interest included? 9.0 21.0 * 5.4 14.9 *
‘Yes’ answer was used to replace ‘Not applicable’ for item 9 in systematic reviews without a meta-analysis. N.S. 5not statistically significant,
* P!0.05, ** P!0.01, *** P!0.001.
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between China and the USA was statistically nonsignif-
icant using data from all included reviews but statisti-
cally significant after excluding Cochrane reviews
(Table 3). The included reviews were ranked into three
groups according to summary AMSTAR scores (low,
moderate, or high), and the proportions of systematic re-
views belonging to each of the groups are shown in
Fig. 1. The difference in proportions between the two
countries was statistically significant. Compared with
systematic reviews from the USA, those from China
were less likely to have a low summary AMSTAR score
and more likely to have a moderate summary AMSTAR
score. Reviews from China were less likely to have a
high AMSTAR score by using data from all systematic
reviews, although it was no longer the case after
excluding Cochrane reviews (Fig. 1).Table 3. The summary PRISMA and AMSTAR scores by country
China
n Mean (95% CI)
Summary AMSTAR score
All systematic reviews 100 6.7 (6.5 to 7.0)
Non-Cochrane reviews 92 6.5 (6.2 to 6.7)
Summary PRISMA score
All systematic reviews 100 21.2 (20.7 to 21.6)
Non-Cochrane reviews 92 21.0 (20.5 to 21.5)
Student t test was used for the difference in the mean summary scor
* P!0.05, ** P!0.01, *** P!0.001.3.3. Results of reporting quality
Table 4 shows proportions of systematic reviews with
total compliance for each of the 27 PRISMA items. Consid-
ering all the included systematic reviews, the differences
between China and the USA were statistically significant
for 11 of the 27 PRISMA items. Compared with systematic
reviews from the USA, those from China had a lower total
compliance in reporting of review protocols, study selec-
tion methods, additional analysis methods, and funding
sources. On the contrary, systematic reviews from China
had a higher proportion of total compliance in reporting
of titles, eligibility criteria, methods for assessing risk of
bias within studies, results of risk of bias within studies,
results of individual studies, results of evidence synthesis,
and discussion of conclusions. After excluding Cochrane
reviews, differences in reporting of titles and protocolThe USA Statistical
significancen Mean (95% CI)
100 6.6 (6.1 to 7.1) N.S.
74 5.7 (5.2 to 6.1) ***
100 20.6 (19.9 to 21.3) N.S.
74 19.8 (19.0 to 20.6) *
e between China and the USA. N.S. 5 statistically non-significant,
All included systema?c reviews
Non-Cochrane systema?c reviews
18%
65%
16%
41%
47%
12%
0%
10%
20%
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AMSTAR score
China
USA
18%
60%
22%
30%
40%
30%
0%
10%
20%
30%
40%
50%
60%
70%
Low
(0-5)
Moderat
(6-7)
High
(8-11)
AMSTAR score
China
USA
Fig. 1. The summary AMSTAR score by country. The difference in pro-
portions between China and the USA was statistically significant
(P 5 0.016 for all systematic reviews and P 5 0.007 for non-
Cochrane systematic reviews).
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significant, whereas differences in structured abstract and
reporting of risk of bias across studies became statistically
significant (Table 4).
The difference in the mean summary PRISMA score was
nonsignificant using data from all included reviews and was
statistically significant after excluding Cochrane reviews
(Table 3). Fig. 2 shows the proportions of systematic
reviews stratified into three groups according to summary
PRISMA scores (low, moderate, or high). Using data from
all included systematic reviews, the difference in the
proportion between the two countries was statistically
nonsignificant. After excluding Cochrane reviews, the over-
all difference was statistically significant, indicating that
systematic reviews from China were less likely to have a
low PRISMA score and more likely to have a high PRISMA
score, compared with those form the USA (Fig. 2).
3.4. Results of regression analyses
Using data from all included systematic reviews, the
summary AMSTAR scores were not statistically signifi-
cantly associated with country in either bivariate or multiple
variable linear regression analyses after adjusting for factorswith imbalanced distribution between China and the USA
(Supplementary File 4 at www.jclinepi.com). After
excluding Cochrane reviews, the summary AMSTAR scores
were statistically significantly associated with country in
bivariate analysis, although it was no longer significant after
adjusting for other factors. Similarly, the summary PRISMA
scores were not significantly associated with country when
all systematic reviews were included in regression analyses.
For non-Cochrane reviews, the association between the
summary PRISMA score and country was statistically sig-
nificant in bivariate analysis, and the association became
statistically nonsignificant in multiple variable analysis
(Supplementary File 4 at www.jclinepi.com).4. Discussion
There were significant differences in characteristics of
systematic reviews between the two countries, regarding
the use of meta-analysis, being a Cochrane review, impact
factor of journals in which they were published, and coau-
thors from multiple countries. The overall differences in the
methodological and reporting quality of systematic reviews
between China and the USA were not statistically signifi-
cant after adjusting for multiple review characteristics.
Of the included systematic reviews, 8 from China and 26
from theUSAwereCochrane systematic reviews. The quality
of Cochrane systematic reviews was better than that of non-
Cochrane reviews in the current study, which is consistent
with findings from the previous studies [13,24]. Cochrane
systematic reviews do not use ‘‘systematic review’’ or
‘‘meta-analysis’’ terms in titles, and all are required to register
their protocols. After excluding Cochrane reviews, differ-
ences between the two countries in the reporting of titles
and predefined protocols were no long statistically
significant.
Using the AMSTAR and PRISMA criteria as the ‘‘gold
standard,’’ systematic reviews from either China or the
USA need to be further improved, as systematic reviews
from any other countries. For example, systematic reviews
from different countries published in 2014 often failed to
provide important aspects of review methods, did not
search for unpublished studies, and used inappropriate
statistical methods [13]. The current study found that
systematic reviews from China had poor methodological
quality in terms of a priori design, listing of excluded
studies, and stating sources of support in both the review
and included primary studies. Only 5.4% of non-
Cochrane systematic reviews from China (vs. 14.9% from
the USA) adequately assessed the conflict of interests in
primary studies included.
Compared with systematic reviews from the USA, those
from China had relatively better methodological quality in
duplicate study selection and in duplicate data extraction.
The number of authors of systematic reviews from China
was on average larger than that from the USA, and the
Table 4. The reporting quality of systematic reviews by country e results of the PRISMA checklist assessment
Section Topic
All systematic reviews Non-Cochrane reviews
China
(n [ 100) %
USA
(n [ 100) % P value
China
(n [ 92) %
USA
(n [ 74) % P value
Title 1. Title 88.0 72.0 ** 91.3 93.2 N.S.
Abstract 2. Structured summary 95.0 87.0 N.S. 94.6 82.4 *
Introduction 3. Rationale 100 100 100 100
4. Objectives 94.0 95.0 N.S. 93.5 93.2 N.S.
Methods 5. Protocol and registration 12.0 27.0 * 5.4 5.4 N.S.
6. Eligibility criteria 93.0 82.0 * 92.4 77.0 *
7. Information sources 100 99.0 N.S. 92.0 73.0 N.S.
8. Search 25.0 39.0 N.S. 19.6 20.6 N.S.
9. Study selection 32.0 52.0 ** 27.2 46.0 *
10. Data collection process 71.0 69.0 N.S. 68.5 62.2 N.S.
11. Data items 71.0 58.0 N.S. 72.8 59.5 N.S.
12. Risk of bias in individual studies 95.0 68.0 *** 94.6 58.1 ***
13. Summary measures 97.0 93.0 N.S. 96.7 90.5 N.S.
14. Synthesis of results 98.0 93.0 N.S. 97.8 94.6 N.S.
15. Risk of bias across studies 68.0 68.0 N.S. 66.3 67.6 N.S.
16. Additional analyses 57.0 82.0 *** 54.4 81.1 ***
Results 17. Study selection 89.0 92.0 N.S. 88.0 89.2 N.S.
18. Study characteristics 97.0 95.0 N.S. 96.7 94.6 N.S.
19. Risk of bias within studies 64.0 51.0 *** 64.0 35.1 ***
20. Results of individual studies 93.0 82.0 * 92.4 77.0 **
21. Synthesis results 98.0 87.0 *** 97.8 85.1 ***
22. Risk of bias across studies 53.0 41.0 N.S. 56.5 40.5 *
23. Additional analysis 46.0 48.0 N.S. 47.8 51.4 N.S.
Discussion 24. Summary of evidence 100 96.0 N.S. 100 96.0 N.S.
25. Limitations 85.0 79.0 N.S. 83.7 77.0 N.S.
26. Conclusions 78.0 62.0 * 77.2 50.0 ***
Funding 27. Funding 20.0 60.0 *** 18.5 58.1 ***
Proportions of total compliance for each item. P values were results of chi-squared testing of total compliance, partial compliance or no
compliance. N.S. 5not statistically significant, * P!0.05, ** P!0.01, *** P!0.001.
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study selection and data extraction. In addition, systematic
reviews from China had better quality in terms of the
assessment of scientific quality of studies, use of quality
assessment in formulating conclusions, and assessment of
publication bias. However, there are still considerable
rooms for further improvement by authors from China in
these items. For example, 20.6% of the included systematic
reviews from China did not appropriately incorporate the
scientific quality of the included studies in formulating con-
clusions, and 37.0% did not assess the risk of publication
bias. Even there were no significant differences between
the two countries, further improvement is also required.
For example, literature search was not sufficiently compre-
hensive in 23.9%, and the status of publication (such as
gray literature) was not used as an inclusion criterion in
as high as 79.3% of systematic reviews from China.
Therefore, appropriate training should be provided to
authors of systematic reviews in China to avoid or reduce
the methodological shortcomings identified in this study.
It should be emphasized that the improvement in methodo-
logical quality is also relevant to authors from the USA and
likely to be relevant to systematic reviews by authors from
any countries [13].
The validity and quality of findings from primary
research conducted in China have been assessed in someprevious studies. For example, controlled trials of acupunc-
ture in China reported more positive results than those from
England, possibly due to publication bias [25]. Another
study found that the reporting quality and validity of RCTs
in China was low, compared with ‘‘gold standard’’ trials
reported in European and North American journals [26].
More recently, Yao et al. [18] reported that quality of
evidence included in meta-analyses published in Chinese
language was lower than that in Cochrane systematic
reviews. However, it is important to distinguish the concep-
tual difference between the quality of primary research and
the quality of systematic reviews. Irrespective of quality of
primary research studies, high-quality systematic reviews
can be conducted to correctly indicate the credibility of
the available evidence.
Primary research in China, as in other low- and middle-
income countries (LMICs), has been rather limited in quan-
tity and quality. For example, 78% of RCTs of interventions
for major NCDs recruited patients in high-income countries,
and risk of bias was higher in RCTs from LMICs [27]. Clin-
ical and public health practice in China (as in other LMICs)
will currently have to be based on research evidence mainly
from high-income countries. Evidence-based health policy
and clinical guidelines in China need sufficient capacity of
systematic reviewing to borrow research evidence from other
countries. In addition, the improved capacity in conducting
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Fig. 2. The summary PRISMA score by country. The difference
between China and the USA was statistically nonsignificant for all
systematic reviews (P 5 0.089) and statistically significant for non-
Cochrane reviews (P 5 0.029).
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valid primary research in China [28]. Therefore, we should
celebrate the success of International Cochrane Collabora-
tion and other evidence-based medicine efforts to increase
the number and to improve the quality of systematic reviews
globally during the past two decades. The concern recently
raised about the redundant publication of systematic reviews
[11,29,30] should be resolved by rigorous peer reviewing
and editorial process [8,31].4.1. Strengths and limitations
According to our knowledge, this is the first study to
compare the methodological and reporting quality of sys-
tematic reviews from China and the USA. Recent system-
atic reviews of RCTs on health care interventions from
the two countries were randomly selected without restric-
tion about medical field or type of interventions, so that
the results would be widely generalizable and reflecting
the present circumstances. Consequently, the included sys-
tematic reviews were diverse in terms of disease conditions,
interventions evaluated, and other review characteristics.Studies in future may consider to compare the quality of
reviews from different countries on the same topic in terms
of patients and interventions evaluated. We used regression
analyses to adjust for multiple review characteristics in the
comparison of the quality of systematic reviews between
the two countries. The results of multiple variable analyses
should be interpreted with caution because of the possible
multicollinearity between independent variables.
Only the assessment of methodological quality using the
AMSTAR checklist was conducted by two independent re-
viewers in this study, and the assessment of PRISMA report-
ing quality was conducted by one reviewer and checked by a
second reviewer. In addition, the assessment of methodolog-
ical quality of systematic reviews was based on what was re-
ported by authors, and the actual conduct might be different.
We reported results of the methodological and reporting
quality of systematic reviews by checklist items and as the
summary quality scores. Although the use of the summary
AMSTAR score for assessing the methodological quality
of systematic reviews was validated in the previous studies
[20], the PRISMA checklist was not originally designed as
a scored instrument [23], and further studies are required
to assess the validity of the summary PRISMA score for
the reporting quality of published systematic reviews. As
in a previous study [20], we calculated and presented the
mean AMSTAR and PRISMA summary scores in the cur-
rent study. However, further studies are required to explore
the appropriate statistical methods for estimating an average
value of the quality scores of multiple systematic reviews.
The current study included only systematic reviews
from China and the USA and assessed only systematic re-
views of RCTs and published in English. Further studies
are required to compare the quality of systematic reviews
between other countries, published in different languages,
and included observational studies. Another limitation of
the current study is that the representativeness of the
randomly selected systematic reviews was not assessed.
The number of the included systematic reviews was based
on the available time and other resources, and sample size
required was not formally calculated because of no infor-
mation on the meaningful difference in reporting or meth-
odological quality of systematic reviews between
countries. It may be interesting to note that the current
study included a total of 100 systematic reviews from each
of the two countries, twice more than the number of meta-
analyses (n 5 50) from each of the two countries included
in a previous study [12].5. Conclusions
The overallmethodological and reporting quality of system-
atic reviews by authors from China were similar to those from
the USA, although the quality of systematic reviews from both
countries could be further improved. Identified shortcomings in
methodological and reporting quality of published systematic
9J. Tian et al. / Journal of Clinical Epidemiology - (2017) -reviews should be taken into consideration in further training of
authors of systematic reviews in the relevant countries.Acknowledgments
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